Literature DB >> 9925184

An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.

J Zhang-Wong1, M Beiser, R B Zipursky, G Bean.   

Abstract

The objective of this study was to examine neuroleptic effectiveness among Asians and Caucasians, and to investigate inter-ethnic pharmacodynamic differences. Asians and Caucasians suffering a first episode of psychosis were maintained on low oral doses of haloperidol (2 mg/day) for the first week of treatment. Doses were increased weekly until the optimal therapeutic dosage was achieved. This was defined as the point at which subjects: (a) experienced significant clinical improvement; or (b) developed extrapyramidal side effects. Plasma haloperidol and prolactin were measured at intake, at the end of first week of the treatment on haloperidol 2 mg/day, and at optimal therapeutic dosage. The average optimal dosage for Asians and Caucasians was equal. However, at the end of the first week of haloperidol at a fixed dose of 2 mg, Caucasian males had significantly lower plasma haloperidol levels than Asian males while no ethnic differences in haloperidol levels were found among females. There were no ethnicity or gender effects on plasma prolactin response after 1 week of treatment. Ethnicity and gender may affect haloperidol metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9925184     DOI: 10.1016/s0165-1781(98)00114-0

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents.

Authors:  Yeni Kim; Soo-Churl Cho; Min-Sup Shin; Jae-Won Kim; Sang-Chul Choi; Boong-Nyun Kim
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

Review 2.  Culturally competent systems of care for children's mental health: advances and challenges.

Authors:  Andrés J Pumariega; Kenneth Rogers; Eugenio Rothe
Journal:  Community Ment Health J       Date:  2005-10

Review 3.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Hiroyoshi Takeuchi; Kensuke Nomura; Akira Tanabe; Koichiro Watanabe; Gohei Yagi; Haruo Kashima
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

5.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

6.  The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999.

Authors:  Gabor S Ungvari; Yiu Gar Chung; Yip Ka Chee; Ng Fung-Shing; Tang Wai Kwong; Helen F K Chiu
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

7.  Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study.

Authors:  Florian Brettner; Silke Janitza; Kathrin Prüll; Ernst Weninger; Ulrich Mansmann; Helmut Küchenhoff; Alexander Jovanovic; Bernhard Pollwein; Daniel Chappell; Bernhard Zwissler; Vera von Dossow
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

8.  Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia.

Authors:  Hiroko Shimizu; Martine Neyens; Marc De Meulder; Srihari Gopal; Yuko Tsukamoto; Mahesh N Samtani; Bart Remmerie
Journal:  Clin Pharmacol Drug Dev       Date:  2019-12-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.